Size : | Price | Quantity | |
---|---|---|---|
10 mg | $50.00 | ||
50 mg | $175.00 |
Vatalanib 2HCl (212141-51-0) is a potent, selective inhibitor of the VEGFR tyrosine kinases VEGFR-1 (Flt-1, IC50 = 77 nM) and VEGFR-2 (FLK-1/KDR, IC50 = 37 nM).1 Weaker inhibitor of other tyrosine kinases including PDGFR-β (IC50 = 580 nM), c-KIT (IC50 = 730 nM), FLT-4 (IC50 = 660 nM) and c-FMS (IC50 = 1.4 μM). Inactive against the EGFR, c-SRC, v-ABL, and protein kinase Cα (IC50 > 10 μM). Vatalanib 2HCl inhibits the growth of multiple myeloma cells in the bone marrow microenvironment.2
References/Citations:
1) Wood et al. (2000), PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration; Cancer Res., 60 2178
2) Lin et al. (2002), The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in bone marrow microenvironment; Cancer Res., 62 5019
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Vatalanib 2HCl (212141-51-0) is a potent, selective inhibitor of the VEGFR tyrosine kinases VEGFR-1 (Flt-1, IC50 = 77 nM) and VEGFR-2 (FLK-1/KDR, IC50 = 37 nM).1 Weaker inhibitor of other tyrosine kinases including PDGFR-β (IC50 = 580 nM), c-KIT (IC50 = 730 nM), FLT-4 (IC50 = 660 nM) and c-FMS (IC50 = 1.4 μM). Inactive against the EGFR, c-SRC, v-ABL, and protein kinase Cα (IC50 > 10 μM). Vatalanib 2HCl inhibits the growth of multiple myeloma cells in the bone marrow microenvironment.2
References/Citations:
1) Wood et al. (2000), PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration; Cancer Res., 60 2178
2) Lin et al. (2002), The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in bone marrow microenvironment; Cancer Res., 62 5019
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.